Parametric Portfolio Associates LLC increased its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 1.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 653,327 shares of the biotechnology company’s stock after purchasing an additional 9,631 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Grifols, were worth $13,805,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of GRFS. Quantbot Technologies LP lifted its stake in shares of Grifols, by 86.8% during the 1st quarter. Quantbot Technologies LP now owns 8,122 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 3,774 shares during the last quarter. Stifel Financial Corp increased its position in Grifols, by 4.3% during the 1st quarter. Stifel Financial Corp now owns 11,630 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 476 shares in the last quarter. Stevens Capital Management LP acquired a new position in Grifols, during the 2nd quarter valued at about $236,000. Advisor Group Inc. increased its position in Grifols, by 2.8% during the 2nd quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 309 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in Grifols, by 16.1% during the 1st quarter. Ameriprise Financial Inc. now owns 13,277 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 1,839 shares in the last quarter. Hedge funds and other institutional investors own 21.93% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/09/parametric-portfolio-associates-llc-has-13-81-million-position-in-grifols-s-a-grfs.html.

Grifols, S.A. (NASDAQ:GRFS) opened at 21.12 on Monday. Grifols, S.A. has a 12 month low of $14.27 and a 12 month high of $22.83. The firm has a market capitalization of $28.86 billion, a price-to-earnings ratio of 42.97 and a beta of 0.98. The company’s 50-day moving average price is $20.93 and its 200 day moving average price is $20.69.

GRFS has been the topic of several recent analyst reports. BidaskClub raised Grifols, from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Goldman Sachs Group, Inc. (The) lowered Grifols, from a “buy” rating to a “neutral” rating in a research report on Friday, June 30th. Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols, in a research report on Tuesday, July 4th. Finally, Zacks Investment Research raised Grifols, from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Tuesday, July 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Grifols, has a consensus rating of “Hold” and a consensus target price of $24.00.

About Grifols,

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS).

Institutional Ownership by Quarter for Grifols, (NASDAQ:GRFS)

Receive News & Stock Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related stocks with our FREE daily email newsletter.